Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ: BLUE )

8.223 +0.213 (+2.67%)
Streaming Delayed Price Updated: 10:05 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about bluebird bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
An expected big win is rapidly turning into a defeat. 
Via The Motley Fool
Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
4 Analysts Have This to Say About bluebird bio
Via Benzinga
What's Going On With Bluebird Bio Stock?
Bluebird Bio, Inc. 
Via Benzinga
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%
Wall Street always think companies are high-growth potential stocks but a little circumspection is required before buying 
Via InvestorPlace
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
2 Biotech Stocks That Could Soar in December
These two biotechs have important catalysts coming up in December. 
Via The Motley Fool
Is Bluebird Bio Stock a Buy?
This biotech looks cheap, but is it a value trap? 
Via The Motley Fool
Where Will Bluebird Bio Be in 1 Year?
Things could get better for the biotech, but they could also get worse. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
What's Going On With Bluebird Bio Stock?
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading higher Monday after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American... 
Via Benzinga
Cigna Calls Off Humana Merger, Joins Macy's, Snap And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow Jones futures trading almost flat on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
These 2 Stocks Could Be About to Soar: Are They Buys?
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares... 
Via Benzinga
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024. 
Via The Motley Fool
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.